The Effect of Different Luteal Phase Support Applications on Clinical Pregnancy Outcomes in Frozen-Thawed Embryo Transfer

Table 1

Demographic data and treatment results of the females participating in the study.

		(%)
Treatment agent
Crinone	57	34.8
Duphaston	30	18.3
Progestan	77	47
Age groups
<30	41	25
30-35	59	36
>35	64	39
The cause of infertility
Male	46	28
Female	75	45.7
Male and female	25	15.2
Unknown	18	11
Pregnancy
No	72	43.9
Yes	92	56.1
	Mean (SD)	Median (min-Q1-Q3-max)
Age	33.24 (5.64)	33 (20-29.5-38-45)
BMI	25.15 (4.49)	24.23 (17.3-22-27.5-40)
FSH	8.28 (3.44)	7.43 (2.35-6.32-9.72-23.77)
LH	5.89 (2.64)	5.46 (0.42-3.95-7.56-14.9)
AMH	3.15 (3.18)	1.96 (0.01-0.96-4.58-15)
TSH	2.08 (1.08)	1.87 (0.12-1.41-2.55-6.03)
Basal E2	43.2 (14.71)	41.23 (12-32.1-50.3-97.27)
Transfer E2	396.27 (202.2)	354.5 (105.4-233.71-527.46-979)
Difference E2 (transfer-basal)	353.08 (201.64)	310.9 (44.59-193.74-489.33-951.1)
Basal progesterone	0.66 (0.31)	0.63 (0.14-0.42-0.86-1.76)
Transfer progesterone	20.36 (17.48)	14.35 (1.28-8.65-23-80)
The difference in progesterone (transfer-basal)	19.7 (17.5)	13.72 (0.8-8.02-22.03-78.69)
Endometrium (mm)	10.55 (2.16)	10.2 (7-9-12-22)
Number of attempts	1.7 (1.14)	1 (1-1-2-8)

SD.: standard deviation; min: minimum; Q1: percentile 25; Q3: percentile 75; max: maximum.